| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5614520 | TAKEDA PHARMS USA | 2-arylthiazole derivatives and pharmaceutical composition thereof |
Mar, 2019
(5 years ago) | |
| US6225474 | TAKEDA PHARMS USA | Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7361676 | TAKEDA PHARMS USA | Solid preparation containing single crystal form |
Mar, 2024
(a month ago) | |
| US8372872 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(7 years from now) | |
| US9107912 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(7 years from now) | |
Uloric is owned by Takeda Pharms Usa.
Uloric contains Febuxostat.
Uloric has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Uloric are:
- US7361676
- US5614520
- US6225474
Uloric was authorised for market use on 13 February, 2009.
Uloric is available in tablet;oral dosage forms.
Uloric can be used as use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline, chronic management of hyperuricemia in patients with gout. not recommended for the treatment of asymptomatic hyperuricemia.
Drug patent challenges can be filed against Uloric from 13 February, 2013.
The generics of Uloric are possible to be released after 08 September, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-205) | Aug 15, 2020 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2014 |
Drugs and Companies using FEBUXOSTAT ingredient
NCE-1 date: 13 February, 2013
Market Authorisation Date: 13 February, 2009
Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline; Chronic management of hyper...
Dosage: TABLET;ORAL
ULORIC family patents
